The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies

The tumor microenvironment (TME) is a dynamic ecosystem that actively shapes cancer progression, therapeutic resistance, and immune escape. It comprises malignant cells, stromal and endothelial cells, extracellular matrix components, and infiltrating immune populations with both pro- and anti-tumor functions. While immune surveillance can eliminate transformed cells early in tumorigenesis, established malignancies undergo immunological and metabolic reprogramming that enables immune evasion and a durable suppressive niche, defined by accumulation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), regulatory B cells (Bregs) and tolerogenic dendritic cells (DCs). These populations inhibit cytotoxic T lymphocytes and natural killer cells via inhibitory cytokines, checkpoint engagement, metabolic competition, nutrient depletion, and immunosuppressive metabolites. Beyond classical regulatory signaling, metabolic remodeling is a central driver of immune suppression. Enhanced glycolysis and mitochondrial reprogramming in cancer cells cause nutrient depletion, hypoxia, and acidification, impairing immune-cell differentiation and function. Suppressive populations adapt by preferentially using oxidative phosphorylation, fatty acid oxidation, amino acid metabolism, and tumor-derived metabolites such as lactate, adenosine, and kynurenine, actively reinforcing immunosuppression. Lactate also signals to drive regulatory immune-cell differentiation, while tryptophan catabolism and adenosine signaling act as metabolic immune checkpoints that suppress effector lymphocytes. This review synthesizes the cellular and metabolic architecture of the immunosuppressive TME, highlighting bidirectional interactions between metabolic stress and immune dysfunction that drive tumor progression and therapy resistance, and discusses emerging therapeutic strategies targeting immunometabolic pathways, including reprogramming of suppressive populations and combination approaches pairing metabolic interventions with checkpoint blockade and adoptive cellular therapies.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223678
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies

Maria A. Paschou, Constantin N. Baxevanis, Angelos D. Gritzapis, Nikolaos Angelis et al.
4 links
Cancers
Cancer Immunotherapy and Biomarkers
article

The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies

Maria A. Paschou, Constantin N. Baxevanis, Angelos D. Gritzapis, Nikolaos Angelis, Ourania Tsitsilonis
article en

Abstract

The tumor microenvironment (TME) is a dynamic ecosystem that actively shapes cancer progression, therapeutic resistance, and immune escape. It comprises malignant cells, stromal and endothelial cells, extracellular matrix components, and infiltrating immune populations with both pro- and anti-tumor functions. While immune surveillance can eliminate transformed cells early in tumorigenesis, established malignancies undergo immunological and metabolic reprogramming that enables immune evasion and a durable suppressive niche, defined by accumulation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), regulatory B cells (Bregs) and tolerogenic dendritic cells (DCs). These populations inhibit cytotoxic T lymphocytes and natural killer cells via inhibitory cytokines, checkpoint engagement, metabolic competition, nutrient depletion, and immunosuppressive metabolites. Beyond classical regulatory signaling, metabolic remodeling is a central driver of immune suppression. Enhanced glycolysis and mitochondrial reprogramming in cancer cells cause nutrient depletion, hypoxia, and acidification, impairing immune-cell differentiation and function. Suppressive populations adapt by preferentially using oxidative phosphorylation, fatty acid oxidation, amino acid metabolism, and tumor-derived metabolites such as lactate, adenosine, and kynurenine, actively reinforcing immunosuppression. Lactate also signals to drive regulatory immune-cell differentiation, while tryptophan catabolism and adenosine signaling act as metabolic immune checkpoints that suppress effector lymphocytes. This review synthesizes the cellular and metabolic architecture of the immunosuppressive TME, highlighting bidirectional interactions between metabolic stress and immune dysfunction that drive tumor progression and therapy resistance, and discusses emerging therapeutic strategies targeting immunometabolic pathways, including reprogramming of suppressive populations and combination approaches pairing metabolic interventions with checkpoint blockade and adoptive cellular therapies.

CancersVol. 18(22)
National and Kapodistrian University of Athens (GR), St Savas Hospital (GR)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon